Navigating the CMS 14-Day Rule in Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

January 17, 2019

Identifying and Solving Top Challenges to Oncology Biomarker Testing

Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of [ Read More ]

November 10, 2012

PMO Interview with the Innovator Series: Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, [ Read More ]